Walter Public Investments Inc. Decreases Stake in Icon Plc $ICLR

Walter Public Investments Inc. lessened its holdings in shares of Icon Plc (NASDAQ:ICLR) by 20.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 80,757 shares of the medical research company’s stock after selling 20,524 shares during the quarter. Icon makes up about 2.3% of Walter Public Investments Inc.’s portfolio, making the stock its 24th biggest holding. Walter Public Investments Inc. owned approximately 0.10% of Icon worth $14,132,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Private Trust Co. NA boosted its position in Icon by 200.0% during the third quarter. Private Trust Co. NA now owns 141 shares of the medical research company’s stock worth $25,000 after acquiring an additional 94 shares during the last quarter. Ameritas Advisory Services LLC acquired a new position in shares of Icon during the 2nd quarter worth approximately $48,000. LRI Investments LLC purchased a new stake in shares of Icon in the second quarter valued at approximately $49,000. Blue Trust Inc. grew its position in shares of Icon by 44.0% in the second quarter. Blue Trust Inc. now owns 393 shares of the medical research company’s stock valued at $57,000 after purchasing an additional 120 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its position in Icon by 40,800.0% during the second quarter. Caitong International Asset Management Co. Ltd now owns 409 shares of the medical research company’s stock worth $59,000 after buying an additional 408 shares in the last quarter. 95.61% of the stock is currently owned by institutional investors and hedge funds.

Icon Price Performance

Shares of ICLR opened at $184.77 on Thursday. The firm has a 50-day simple moving average of $178.31 and a two-hundred day simple moving average of $173.69. The stock has a market cap of $14.92 billion, a PE ratio of 25.00, a P/E/G ratio of 3.86 and a beta of 1.26. Icon Plc has a 1-year low of $125.10 and a 1-year high of $211.00. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.06 and a quick ratio of 1.06.

Analyst Ratings Changes

Several brokerages have issued reports on ICLR. Truist Financial restated a “hold” rating and issued a $222.00 target price (down from $231.00) on shares of Icon in a report on Thursday, January 8th. Barclays upped their price objective on shares of Icon from $185.00 to $200.00 and gave the company an “equal weight” rating in a report on Monday, December 15th. Mizuho set a $216.00 target price on shares of Icon in a research note on Friday, January 9th. Weiss Ratings reiterated a “hold (c)” rating on shares of Icon in a report on Monday, December 29th. Finally, TD Cowen cut their price target on shares of Icon from $183.00 to $172.00 and set a “hold” rating for the company in a report on Friday, October 24th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and twelve have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Icon presently has a consensus rating of “Moderate Buy” and an average target price of $199.87.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.